Summary of COVID-19 donidalorsen studies

1. Zampieri et al., Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial

111 patient donidalorsen late treatment RCT: 151% higher mortality (p=0.08), 81% higher ventilation (p=0.08), and 35% higher progression (p=0.03).
RCT 111 hospitalized COVID-19 patients in Brazil showing no clinical benefit with antisense therapy to block the kallikrein-kinin pathway using ISIS 721744 (donidalorsen). Treatment was associated with a significantly higher SOFA score at day 15 and with a significantly higher risk of adverse events.
Aug 2024, J. Critical Care, https://www.sciencedirect.com/science/article/pii/S0883944124003794, https://c19p.org/zampieri